| 1 | screening and rational design | | | | | | | 5 | 1.64% |
| 2 | design screening and rational | | | | | | | 3 | 0.98% |
| 3 | rational design screening and | | | | | | | 2 | 0.66% |
| 4 | deliver precision medicines for | | | | | | | 2 | 0.66% |
| 5 | to deliver precision medicines | | | | | | | 2 | 0.66% |
| 6 | degradation to deliver precision | | | | | | | 2 | 0.66% |
| 7 | and rational design screening | | | | | | | 2 | 0.66% |
| 8 | venquis therapeutics venquis therapeutics | | | | | | | 2 | 0.66% |
| 9 | therapeuticsvenquis therapeutics harnessing the | | | | | | | 2 | 0.66% |
| 10 | library screening platform to | | | | | | | 1 | 0.33% |
| 11 | identify novel direct protein | | | | | | | 1 | 0.33% |
| 12 | chemical library screening platform | | | | | | | 1 | 0.33% |
| 13 | focused chemical library screening | | | | | | | 1 | 0.33% |
| 14 | a focused chemical library | | | | | | | 1 | 0.33% |
| 15 | developed a focused chemical | | | | | | | 1 | 0.33% |
| 16 | we developed a focused | | | | | | | 1 | 0.33% |
| 17 | kras sparing our lab | | | | | | | 1 | 0.33% |
| 18 | wildtype kras sparing our | | | | | | | 1 | 0.33% |
| 19 | therapeutics venquis therapeutics venquis | | | | | | | 1 | 0.33% |
| 20 | maintain wildtype kras sparing | | | | | | | 1 | 0.33% |
| 21 | novel direct protein degraders | | | | | | | 1 | 0.33% |
| 22 | direct protein degraders we | | | | | | | 1 | 0.33% |
| 23 | protein degraders we simultaneously | | | | | | | 1 | 0.33% |
| 24 | degraders we simultaneously use | | | | | | | 1 | 0.33% |
| 25 | our lab venquis therapeutics | | | | | | | 1 | 0.33% |
| 26 | degraders maintain wildtype kras | | | | | | | 1 | 0.33% |
| 27 | structurebased analog design from | | | | | | | 1 | 0.33% |
| 28 | analog design from known | | | | | | | 1 | 0.33% |
| 29 | design from known chemical | | | | | | | 1 | 0.33% |
| 30 | from known chemical binders | | | | | | | 1 | 0.33% |
| 31 | known chemical binders to | | | | | | | 1 | 0.33% |
| 32 | sparing our lab venquis | | | | | | | 1 | 0.33% |
| 33 | which is then targeted | | | | | | | 1 | 0.33% |
| 34 | degradation screening and rational | | | | | | | 1 | 0.33% |
| 35 | or protacs these directly | | | | | | | 1 | 0.33% |
| 36 | san diego california 92127 | | | | | | | 1 | 0.33% |
| 37 | 105 san diego california | | | | | | | 1 | 0.33% |
| 38 | ste 105 san diego | | | | | | | 1 | 0.33% |
| 39 | degraders these are not | | | | | | | 1 | 0.33% |
| 40 | these are not molecular | | | | | | | 1 | 0.33% |